New therapy to help heal diabetic ulcers
Controlled release of RNA-targeting therapy to promote healing of diabetic ulcers
This study is testing a new treatment to help heal slow-healing diabetic ulcers by using special therapies that target the healing process, making it easier and faster for patients to recover.
Quick facts
| Grant type | Fellowship grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Harvard Medical School NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project ID | NIH-10909095 on NIH RePORTER |
What this research studies
This research focuses on developing a novel therapy to promote healing in diabetic ulcers, which are often slow to heal and can lead to serious complications. The approach involves using RNA-targeting therapies that can directly influence the healing process by addressing the underlying molecular issues that hinder recovery. By utilizing a specialized delivery method that allows for controlled release of these therapies, the research aims to improve the effectiveness of treatment and enhance healing outcomes for patients. This innovative method could potentially transform how diabetic ulcers are treated, making healing faster and more efficient.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals with diabetes who are experiencing non-healing ulcers.
Not a fit: Patients without diabetes or those whose ulcers are not related to diabetic complications may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could significantly improve healing rates for diabetic ulcers, reducing the risk of complications such as amputation.
How similar studies have performed: Previous research has shown promise in using RNA-targeting therapies for wound healing, indicating that this approach could be effective.
Where this research is happening
Boston, United States
- Harvard Medical School — Boston, United States (Active)
Researchers
- Principal investigator: Berger, Adam G — Harvard Medical School
- Study coordinator: Berger, Adam G
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.